updat forecast estim aug
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research aug
estim aug
price data sep
rate updat sep
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
acquisit covidien produc combin
compani forc reckon med-tech
wide rang chronic diseas covidien breadth
product acut care hospit bolster
posit key partner hospit custom
histor focus design manufactur
devic address cardiac care neurolog spinal condit
diabet along firm remain focus
fundament strategi innov often first market
new product invest heavili intern research
develop effort well acquir emerg technolog
howev postreform healthcar world
higher hurdl secur reimburs next-gener
technolog slightli shift strategi focu
partner close hospit client offer greater
breadth product servic help hospit oper
effici partner close integr
hospit oper think well posit
take advantag busi opportun
alway appreci divers portfolio
certain wane product line would off-set growth
categori addit devic consum use
surgic suit stabil potenti speed bump
individu product line continu focu
gener roughli billion chines sale fiscal
broad portfolio product fit well
firm earlier purchas kanghui hold provid
firm establish network nativ distributor
reach thousand hospit china
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
one largest medic devic compani develop
manufactur therapeut medic devic chronic diseas portfolio
spinal fixat devic neurovascular product surgic tool
compani market product healthcar institut physician
unit state oversea foreign sale account
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
deliv anoth quarter impress result
kick fiscal strong start first blush
quarterli perform gener met expect
stand behind fair valu estim per
share adjust sale medic suppli
busi cardin quarterli revenu
increas constant currenc consid
medic technolog market grow
midsingl digit sheer size market
last quarter compani robust top-lin
growth noth sneez underscor
competit strength wide-moat compani
share price steadili climb last six
month believ investor recogn
firm abil sustain top- bottom-lin growth
previou quarter perform reflect
substanti line-up new product gain strong
adopt includ high teen growth tavr heart
valv launch coronari stent resolut onyx
addit signific contribut advanc stapl
neurovascular although often written
forward-look approach leverag new
opportun offer
value-bas
reimburs investor lose sight firm
abil innov technolog front remain
critic factor success addit
intern gener advanc intelli platform
chronic pain adaptivestim mri compat
remain strong posit vie purchas
shift
final saw low-single-digit growth
cardiac rhythm manag may sound impress
absolut howev abbott
launch compar devic recent
wane product cycl typic see slight
declin firm manag stay
posit territori thank risk-bas contract
tyrx antibacteri envelop devic
novel approach type contract make firm
med-tech compani may also seek risk-bas
contract opportun think expertis conduct
analyz clinic studi critic pull
research develop pay dividend
come risk-bas contract
also help mani devic captur
lot medic data firm signific experi
clinic data leav well-posit work directli
payer addit provid competitor abl
climb learn curv quickli expect dynam
solidifi competit advantag
hold steadi fair valu estim per
share incorpor fairli optimist expect
cardiovascular diabet
neurovascular unit well
expans follow sale legaci covidien medic
suppli busi
shed busi project
averag annual top-lin growth remain
product line incorpor lukewarm growth
cardiac rhythm manag declin
spine
howev expect new neuromodul
indic drug-elut balloon insulin pump
on-going develop atrial fibril market
corevalv sale defend price eros near
revenu growth restor therapi group
fiscal driven resumpt healthcar
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
regain double-digit growth seen howev
biggest wild card quickli
introduc meaning innov support
favor clinic evid magnitud product
pull-through emerg new partnership
outsourc agreement forg
hospit client firm new product surpris us
upsid increment product revenu associ
servic agreement exceed expect firm
lower manufactur cost wring
administr save expect next
year fair valu estim would rise
hand cardiovascular divis remain
mire low-single-digit growth indic expans
corevalv fail spine fall expect
product pull-through emerg fair valu
estim would fall per share
wide moat root domin presenc
highli engin medic devic treat chronic
diseas includ beyond histor stronghold
heart diseas moat come sever
cardiac area compet roughli three
competitor total across heart-rel portfolio
market pacemak icd coronari stent heart valv
neuromodul gener oper
spine area moat strengthen high
switch cost surgeon doctor often reli medic
devic sale rep deep devic knowledg well
experi devic usag wide rang
patient result rep play role highli
special expert advis practition
implant program mainten medtron
util adopt new technolog
neuromodul neurovascular
legaci gross margin histor
held firm addit covidien lower
roughli basi point anticip
compani eke increment improv
next five year firm ration manufactur
asset project normal gross margin closer
longer term expect cost synergi
emerg sale administr thank
cross-sel bundl product servic
base averag volatil cash flow divers
product portfolio rel less discretionari therapeut
market rate uncertainti medium
base case assum see
low-single-digit growth busi concern
overus damp sale off-set strength atrial
fibril endovascular structur heart surgic
technolog expect spinal devic infus
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
devic creat sticki relationship medic
practition dynam tend keep spinal surgeon
loyal product long compani
fall far behind competitor come
final wide moat bolster sever
intang includ intellectu properti care
nurtur relationship physician thank
persist abil innov often first
market new product variou therapeut area
expect continu record innov base
extens patent portfolio accord independ
patent board hold strongest
intellectu properti posit base number
technolog strength patent
portfolio allow better weather occasion glitch
develop approv process particular new
devic invest neuromodul diabet
spinal product middl late paid
spade although spine
busi hit slower market growth sinc
firm seen double-digit growth diabet
atrial fibril segment
product line wane new clinic data alter
treatment guidelin firm continu invest
emerg technolog includ renal denerv
transcathet mitral valv drive futur growth
addit covidien deepen competit
advantag covidien medic devic segment enjoy
brand recognit technolog innov substanti
record enhanc
increment research invest past year
result steadi stream product upgrad
new technolog covidien devic subseg
oper oligopolist fashion absenc irrat
price competit evolutionari
rather
revolutionari natur innov tend lead
margin share shift industri strong excess
return covidien current rank near top
product categori compet devic vie
mainli johnson johnson rest field
fragment compani
occupi product nich rather compet broadli
big two
seen new entrant make signific inroad
new competitor sometim pop margin rang
less sophist discount price high-end
technolog advanc rare result
defens practition rare switch
competitor product inertia well
up-front train cost surgeon influenc
procur decis arguabl wane establish
player also administr ear covidien
domin number surgic specialti breadth
portfolio render competitor effort displac
cost individu product basi less meaning
moat remain stabl partli thank stabl
oligopoli compet primarili
abbott purchas st jude medic edward
lifesci cardiac devic johnson
johnson hospital-ori surgic devic tool
competitor may trade market share point
sever year rel short product cycl allow
peer regain share fairli quickli
consist control cardiac rhythm
manag market also domin competitor
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
structur heart neuromodul insulin pump
firm continu innov intern well purchas
new complementari technolog remain
forefront medic devic
wake healthcar reform doctor sign
employe healthcar provid think shift
realign doctor financi interest
hospit practic group howev alreadi
maneuv better posit partner
hospit healthcar system doctor see
influenc wane wide-rang product portfolio
particularli suit play role way
competitor introduc servic
wrap around devic
new hospit solut servic taken
big step new role manag catheter
electrophysiolog lab deliv oper
effici think hospit could seek firm
servic turn closer integr
servic hospit oper could also rais
switch cost hospit custom
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
histor held roughli share
core heart devic also market leader
spinal product insulin pump neuromodul
chronic pain
pipelin attract treatment
fibril aortic stenosi variou
neurolog disord new therapi prove
effect could domin three
often find novel way appli familiar
technolog like use implant electron
pacemak
incontin chronic pain
address
technolog may face stiffer fight
maintain leadership arena
devic indirectli subject medicar
increas pressur
oover year issu number
voluntari recal product although
fatal associ problem
effort hurt doctor confid
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
financi health deterior somewhat
financ signific portion covidien merger
new debt issuanc covidien sharehold own
combin entiti time merger
allow combin entiti invert covidien irish
domicil lower tax rate enhanc abil
access oversea cash end januari
owe billion debt around time
adjust ebitda around time
histor sinc firm paid roughli
billion debt plan de-lever near
futur upon sale legaci covidien medic suppli
portfolio think medtron easili
shoulder current debt load beyond debt oblig
firm aim return minimum annual free
cash flow sharehold shoot
dividend pay-out ratio consist engag share
base averag volatil cash flow divers
product portfolio rel less discretionari therapeut
market rate uncertainti medium
babi boomer hit medicar age could futur
cut medicar reimburs device-rel
procedur innov name game medic
devic bar rais wake
healthcar reform success secur price premium
new technolog longer given depend
favor clinic data increas regulatori attent
interest conduct extens clinic trial
aftermarket studi could increas develop cost
product recal liabil inventori
write-down occasion sore spot industri
although depart justic wrap
investig off-label use infus product without
issu charg
controversi around
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
investig ad uncertainti contribut declin
infus sale potenti investig product
market remain risk medic devic
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
repres date owner name posit common share held report holder issuer
share
fund
share
fund
omar ishrak left lead
ceo chairman ishrak littl direct
experi cardiac market devic industri
consid rise star ge ishrak pioneer
behind success entranc china
market -- led effort expand product portfolio
order compet head head local chines imag
compani mindray gave ge substanti
leg midmarket china consid
make number invest china
india identifi emerg market strateg
sourc growth think
perspect parti think push medtron
away -centric past focus organ
close potenti emerg market
moreov drive forc behind
earli effort posit new product servic help
hospit custom improv outcom lower cost -- key
prioriti shift hospit purchas behavior
wake afford act
think recent addit former sell-sid analyst mike
weinstein lead corpor strategi intrigu
move believ weinstein bring deep
well med-tech expertis connect industri
cfo karen parkhil lack came bank
background expect weinstein sharpen
medtron focu activ help streamlin
portfolio includ potenti sale product
busi influenc clarifi firm approach
capit alloc
manag capital-alloc decis
primarili solid occasion misstep come
acquisit like major medic devic
compani make regular acquisit
smaller often privat held firm offer emerg
technolog purchas typic dilut
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
short term technolog still requir much
develop reach commerci though
difficult assess valu purchas
tend view invest akin intern
invest must make main
concern even though seen
pattern goodwil impair hesit poni
gener offer certain acquisit target
seem add valu longer term exampl
spent billion purchas kyphon
acquisit turn disappoint
fewer-than-expect synergi term sale
market physician relationship
abl goos kyphon product back robust
growth howev think mani
acquisit add valu time
corevalv cryocath covidien
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
chang fve may
post strong fiscal fourth-quart result
slightli exceed expect continu hold
temper view increment margin improv
explicit forecast period make minor adjust
assumpt stand behind fair valu
estim weve seen previou quarter wide-moat
saw solid growth key new product
includ intelli spinal cord stimul resolut onyx
drug-elut coronari stent corevalv evolut
transcathet aortic valv particularli pleas
see progress bottom line firm
effici program linger cost synergi
covidien yield basi point improv quarterli
although number product deliv double-digit
growth thank solid adopt insulin pump
star quarter opinion despit earlier issu
suppli capac compani iron
wrinkl full commerci launch ramp sinc
last fall quarterli diabet growth constant
currenc year year anticip pace
continu next two quarter moder
mid-teen growth
medtron abil revit spinal cord stimul
busi chronic pain manag underscor
st jude medic part abbott newcom
introduc meaning improv technolog
found leadership posit market
erod last year howev firm
launch intelli devic offer patient way
toggl back forth high-dos low-dos
therapi anticip medtron claw back
lost share
final bullish resumpt renal
denerv technolog hypertens patient
one hottest emerg technolog
time period cardiac devic maker pursu
minim invas cure hypertens couldnt
control multipl medicationsa market
estim billion howev
medtron pivot studi deliv disappoint result
major competitor halt develop
pipelin product put technolog back
suggest surgic sever renal arteri bring
almost immedi sustain drop blood pressur
challeng replic effect
minim invas measur ablat
portion renal arteri cathet
medtron second whack pivot trial one
third enrol period expect firm
wrap enrol earli fall symplic spyral
devic slightli differ intend affect slightli
differ part anatomi addit compar
first pivot trial second one design includ
pure comparison test procedur
sham procedur without interfer use
hypertens drug overal strong first-
mover posit technolog proven
medtron latest trial end favor result
would expect see abbott jump
renal denerv bandwagon
like pick new senior vice presid
strategi may
interest --
hire longtim sell-sid analyst mike
weinstein head strategi consid weinstein
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
join hold steadi valuat
though continu think share current
under-valued think addit weinstein
bring deep well med-tech expertis connect
industri current cfo karen parkhil lack
came bank background none chang
view wide econom moat stem
intang asset includ intellectu properti broad
relationship practition hospit
expect weinstein sharpen medtron focu
 activ help streamlin portfolio includ
potenti sale product busi
influenc clarifi firm approach capit
alloc follow year tuck-in acquisit
larger purchas covidien truli sprawl
med-tech behemoth singl product unlik
boost sink ship also make difficult
investor understand what drive busi inde
think market doesnt fulli appreci
medtron recent effort forg value-bas contract
hospit help insul firm peak
valley product cycl histor character
cardiac devic industri
expect weinstein contribut posit
medtron strategi oper execut
challeng especi firm breadth
although think subject
extraordinari oper slip-up firm yet
deliv promis margin expans dont
anticip kick fiscal recogn
translat sound strategi oper improv
ultim financi result take time
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end april
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end april
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
